Resources

New platforms and capabilities further enable partners to advance better antibody drugs faster. SAN DIEGO, Calif. – November 15, 2022 ...

SAN DIEGO, Calif. – September 23, 2022 – AlivaMab Discovery Services (“ADS”), a leader in the discovery of superior antibody-based ...

Ablexis’ multi-target licensing agreement grants Almirall rights to use the AlivaMab® Mouse technology for research, development and commercialization of antibodies ...

AbbVie veteran to support rapid growth and new technologies. SAN DIEGO, Calif. – January 11, 2022 – AlivaMab Discovery Services (“ADS”), a ...

Expanded agreement aims to accelerate the discovery of next-generation antibody modalities SAN DIEGO, Calif. – November 1, 2021 – AlivaMab Discovery ...

Agreement aims to accelerate the discovery of new therapeutics SAN DIEGO, Calif. – September 14, 2021 – AlivaMab Discovery Services (“ADS”), a ...

Expansion gives AlivaMab Discovery Services the ability to streamline the transition of drug discovery programs into development SAN DIEGO, Calif ...

ADS announces integrated antibody drug discovery collaboration SAN DIEGO, Calif. – June 3, 2020 – AlivaMab Discovery Services, LLC, a ...

Offers unique resources for COVID-19 therapeutic discovery SAN DIEGO and EMERYVILLE, Calif. – April 22, 2020 – Ablexis, LLC, AlivaMab ...

ADS to provide expertise and capabilities in antibody drug discovery  SAN DIEGO, Calif. –  September 16, 2019 – AlivaMab Discovery ...

Company Expands Team with Veterans of Antibody Discovery and Development   SAN DIEGO, Calif. – February 26, 2019 – AlivaMab ...